X-Chem Licenses Epigenetic Drug Discovery Program to Bayer Pharma AG
WALTHAM, Mass. – February 13, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved a success milestone with Bayer Pharma AG in the multi-target collaboration the companies established in July 2012.
X-Chem First Biotech to Exceed 100 Billion Compounds with its Unique and Proprietary Small Molecule DNA-Encoded Library
WALTHAM, MA, USA – February 4, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its powerful product engine to the generation of novel small molecule therapeutics, today announced that the company has created the first biotech-owned screening library of DNA-encoded small molecules to ever surpass 100 billion compounds.
X-Chem and PsyBrain Establish Partnership to Discover New Psychiatric Medicines
WALTHAM, Mass. – January 10, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into a partnership with PsyBrain, Inc. to discover new drugs for treating psychiatric illnesses.
X-Chem Enters Expanded Global Drug Discovery Collaboration with AstraZeneca
WALTHAM, Mass. – October 3, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target […]
X-Chem Achieves Early Success in Collaboration with AstraZeneca, Licenses Three Drug Discovery Programs
WALTHAM, Mass. – September 24, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved several milestones leading to the licensing of three drug discovery programs by AstraZeneca, in the context of a collaboration the […]
X-Chem and Roche Enter Into Drug Discovery Collaboration and License Agreement
WALTHAM, MA, USA – (July 1, 2010) – X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem’s proprietary platform to the rapid discovery of drug candidates against several of Roche’s high-value therapeutic targets.